Detailing the immune response to TGFB2 in cholestatic liver disease of PSC patients and MDR2KO mice

View Full Paper

Ask AI

Bookmark

Silencing TGF-β2 reduces inflammation in the liver, leading to altered immune cell dynamics.
Key metrics include a decrease in CD45+ cells and an increase in F4/80+ and CD8+ T cells.
Research involves examining MDR2KO mice, a model for primary sclerosing cholangitis and chronic liver inflammation.
Findings may highlight the importance of TGF-β2 in immune regulation and fibrosis in cholestatic liver disease.

Authors

Discussion

No takes yet. Share an insight, caveat, or question.

Analysis details immune modulation by TGF-β2 in cholestatic liver disease, revealing effects on inflammatory cells.

Bötsch et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark